Fed. Circ. Lets Endo Opana Patent Win Stand

Law360, San Diego (June 04, 2014, 10:55 PM ET) -- The Federal Circuit on Tuesday declined bids by Roxane Laboratories Inc. and Actavis Inc. to review a panel’s ruling that settlements allowing the companies to sell generic versions of Endo Pharmaceuticals Inc.’s painkiller Opana ER did not include licenses for later Opana patents.

The appeals court rejected Roxane’s and Actavis’ petitions to rehear the case en banc, letting stand an appellate panel’s ruling in March that Endo’s deals with Actavis and Roxane over sales of generic versions of Opana did not include express or implied licenses...
To view the full article, register now.